Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

@article{Rao2010MatuzumabPE,
  title={Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.},
  author={Sheela Rao and Naureen Starling and Dayle Cunningham and Kate A Sumpter and David Gilligan and Thomas Ruhstaller and Manuel Valladares-Ayerbes and H. Wilke and Carolyn Archer and Raffael Kurek and Claire Beadman and Jacqui Oates},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 11},
  pages={2213-9}
}
BACKGROUND Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated advanced oesophago-gastric (OG) cancer. The aim was to evaluate the efficacy of matuzumab plus ECX versus ECX alone. PATIENTS AND METHODS In this multicentre, randomised open-label phase II study, 72 patients with metastatic OG cancer were randomly assigned to either 800 mg matuzumab weekly plus epirubicin 50 mg/m… CONTINUE READING
37 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer

  • X Zhang, J Xu, L Shen
  • In American Society of Clinical Oncology Annual…
  • 2008

Cetuximab with irinotecan/Na-Fa/5FU as first-line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study

  • MH Moehler, T Trarbach, T Seufferlein
  • In Gastrointestinal Cancers Symposium,
  • 2008

Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy

  • C Funaioli, C Pinto, F De Fabio
  • In American Society Of Clinical Oncology Annual…
  • 2008

Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer

  • S Han, SR Park, K Lee
  • In American Society of Clincal Oncology Annual…
  • 2008
1 Excerpt

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

  • C Pinto, F Di Fabio, S Siena
  • Ann Oncol
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…